



Office: 903-909, 9th Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034, India
Telephone no.: 011-27355742, 71239900(44 Lines), CIN: L74999RJ1992PLC013387

To,
Corporate Services Department,
BSE Ltd.,
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai- 400001

29.11.2025

Dear Sir,

Sub: Outcome of Board Meeting held on November 29, 2025

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors, at its meeting held today i.e. **Saturday, 29th November, 2025, at 903-909, 9th Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034**, have inter-alia considered and approved the following:

- a) Sub-division/split of equity shares of the Company, such that 1 (One) equity share having face value of Rs. 10/- (Rupees Ten only) each, fully paid-up, be sub-divided into 5 (Five) equity shares having face value of Rs. 2/- (Rupees Two only) each, fully paid-up and consequential alteration(s) to the Memorandum of Association of the Company subject to the approval of the Members of the Company, by way of postal ballot and any regulatory/statutory approvals, as may be required under applicable laws.

The Record date for the purpose of sub division/split of equity shares shall be intimated after seeking approval of the Members of the Company.

The Board has approved the notice of Postal Ballot to seek necessary approval of the Members. The said Notice of Postal Ballot shall be submitted to the Stock Exchanges in due course in compliance with the provisions of the Listing Regulations.

Details with respect to sub-division/ split of shares and alteration Memorandum of Association of the Company in as required to be disclosed under Regulation 30 read with Schedule III of the Listing Regulations and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, as **Annexure A** and **Annexure B** respectively.

The meeting of Board of Directors commenced at **10:30 A.M. and concluded at 11:13 A.M.**

The above information will be available on the website of the company i.e www.titanbiotechltd.com and BSE Ltd i.e www.bseindia.com.

Request to kindly take this information on record and acknowledge.

**For and on behalf of
Titan Biotech Limited**

Charanjit Singh
Company Secretary & Compliance Officer
M.No A12726
Encl: As above

Annexure-A

Details as required to be disclosed under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

S.No.	Particulars	Details				
(a)	Split/consolidation ratio;	Sub-division / split of 1 (One) equity share having face value of Rs. 10/- (Rupees Ten only) each, fully paid-up, sub-divided into 5 (Five) equity shares having face value of Rs. 2/- (Rupees Two only) each, fully paid-up.				
(b)	Rationale behind the split /consolidation	To enhance the liquidity of Company's equity shares and to encourage participation of retail investors by making equity shares of the Company more affordable.				
(c)	Pre and post share capital – authorized, paidup and subscribed	Particulars	Pre subdivision / split (As on the date of this intimation)		Post subdivision / split	
			No. of Equity Shares	Face Value (Rs.)	No. of Equity Shares	Face Value (Rs.)
		Authorised Share Capital				
		Equity Shares	1,00,00,000	10	5,00,00,000	2
		Issued Share Capital				
		Equity Shares	82,63,700	10	4,13,18,500	2
		Subscribed and Paid-up Share Capital				
		Equity Shares	82,63,700	10	4,13,18,500	2
(d)	Expected time of completion	Tentatively within 2 (two) months from the date of approval of the Members of the Company.				
(e)	Class of shares which are consolidated or subdivided	Equity shares. The Company has only one class of equity shares.				



TITAN BIOTECH LIMITED

AN ISO 9001:2015 CERTIFIED COMPANY



Office: 903-909. 9th Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034, India
Telephone no.: 011-27355742, 71239900(44 Lines), CIN: L74999RJ1992PLC013387

(f)	Number of shares of each class pre and post split or consolidation	The Company has only one class of equity shares. The details of pre and post capital are mentioned in point 3 above.
(g)	Number of shareholders who did not get any shares in consolidation and their preconsolidation shareholding	Not Applicable.



TITAN BIOTECH LIMITED

AN ISO 9001:2015 CERTIFIED COMPANY



Office: 903-909. 9th Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034, India
Telephone no.: 011-27355742, 71239900(44 Lines), CIN: L74999RJ1992PLC013387

Annexure B

Details as required to be disclosed under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Details	Particulars
Alteration of the Capital Clause of the Memorandum of Association of the company	<p>Clause (5) of the Memorandum of Association of the Company be and is hereby amended by substituting with the following clause:</p> <p><i>“5. The Authorised Share Capital of the Company is Rs. 10,00,00,000 (Ten Crore) divided into 5,00,00,000 (Five Crore) equity shares of Rs. 2/- each.”</i></p>